drugset / Trial / NCT04913272
Clinical Trial To Evaluate Safety And Efficacy Of KT-301 (Formerly US-APR2020) In Subjects With Chronic Kidney Disease Stage IV
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The aim of this Phase 2 study is to evaluate the safety and efficacy of the live biotherapeutic product, KT-301 (formerly US-APR2020), in the management of patients with CKD Stage IV.
Timeline
- Start
- 2021-06-24
- Primary completion
- 2025-09
- Completion
- 2025-12
Outcome
Outcome not reported
Stopped: “Logistics, company reorganization”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | US-APR2020 | Other / unclassified | 4.5e+10 cells | Oral |